Dutch move to boost orphan drug development
This article was originally published in Scrip
Executive Summary
The Dutch authorities have awarded the first two grants intended to help companies planning to submit applications for EU orphan drug designation. One grant is for Prodarsan, a product for Cockayne syndrome, and the other is for a brain cancer treatment.